lewy body dementia

Dementia with Lewy bodies (DLB), also known as Lewy body disease, is a neurodegenerative disease (a synucleinopathy to be specific) related to Parkinson disease. It is reported as the second most common form of dementia following Alzheimer disease, accounting for 15-20% of cases at autopsy.

Epidemiology

Dementia with Lewy bodies presents in older patients (onset typically in 50-70 years of age), and is sporadic .

It is the second most common neurodegenerative cause of dementia in older patients, after Alzheimer disease, accounting for 15-20% of cases .

Clinical presentation

Typically patients first present with a frontal-type dementia with little in the way of memory deficits early in the course of the disease. Core features include :

  • fluctuating cognitive impairment especially in executive function, attention and alertness
  • visuospatial impairment, including visual hallucinations (detailed and vivid)
  • concurrent parkinsonian symptoms may be present but are less common, more frequently occurring years after the onset of dementia

Gastrointestinal symptoms (constipation, gastroparesis, nausea) are also commonly reported due to enteric neuronal dysfunction secondary to the accumulation of Lewy bodies .

Late in the disease quadriplegia and/or apallic syndrome may develop .

Dementia with Lewy bodies vs Parkinson disease dementia

There are three entities to be distinguished in this gamut:

  • Parkinson disease
  • Parkinson disease dementia
  • dementia with Lewy bodies
  • The relationship between Parkinson disease and dementia with Lewy bodies is controversial, with some authors believing they are different manifestations of the same disease, whereas others believe they are distinct entities . This notwithstanding, the main clinical distinction lies in the timing of symptoms.

    In dementia with Lewy bodies, dementia precedes or accompanies parkinsonism (or at least becomes clinically evident within 12 months of presentation ). Patients with Parkinson disease, on the other hand, will not infrequently also develop dementia. However, it typically occurs years after the onset of parkinsonian symptoms . Such cases are then referred to as Parkinson disease dementia (PDD); at least 12 months of Parkinsonism without dementia need to precede cognitive impairment .

    Dementia with Lewy bodies vs Alzheimer disease

    The prominent and fairly initially isolated memory disturbance seen early in the course of classical Alzheimer disease is the main distinguishing clinical feature. Posterior cortical atrophy variant of Alzheimer disease is harder to distinguish especially as it shares some clinical features.

    Cognitive, movement and visual symptoms are treated with their respective medications. Treatment with neuroleptics may exacerbate Parkinsonian symptoms. Therefore a balance must be sought. Cholinesterase inhibitors may be more effective in Lewy body disease than in Alzheimer disease.

    Pathology

    The characteristic feature of dementia with Lewy bodies is (not surprisingly) the accumulation of Lewy bodies throughout the brain. These intracellular inclusions result from the aggregation of misfolded α-synuclein .

    Lewy bodies are seen in greatest concentrations in the midbrain, hypothalamus, basal ganglia, inferior olives, brainstem reticular formation, and dentate nuclei of the cerebellum .

    Neurofibrillary tangles are also present, although unlike those found in Alzheimer disease, they lack an amyloid core .

    Radiographic features

    MRI is the modality of choice to structurally image the brain. Functional imaging with SPECT/PET is also useful.

    MRI

    Unfortunately, the literature is replete with studies showing atrophy in various parts of the brain without a clearly identified unique pattern. Most helpful in distinguishing DLB from other entities resulting in dementia is the absence of features of other diseases.

    Features reported include :

    Perhaps, more importantly, the mesial temporal lobe and hippocampi remain relatively normal in size, helping to distinguish Lewy body disease from Alzheimer disease .

    Nuclear medicine

    Although frontal and temporal hypoperfusion can be similar to that seen in Alzheimer disease, occipital hypoperfusion and the cingulate island sign (preserved metabolism of the posterior cingulate) on SPECT/PET may aid in differentiation from other types of dementia, especially Alzheimer disease .

    Treatment and prognosis

    Unlike Parkinson disease, dementia with Lewy bodies respond less readily to L-dopa and also may have severe sensitivity reactions to neuroleptic drugs, such as rigidity, reduced consciousness, pyrexia, falling, postural hypotension and collapse .

    Lewy body dementia also responds favourably to acetylcholinesterase inhibitors .

    History and etymology

    Lewy body inclusions were first discovered in the early 1900s by the German-born, American neurologist Frederic Lewy . However, the association of dementia with Lewy bodies was first discovered in 1976 by Kenji Kosaka, a Japanese psychiatrist and neuropathologist .

    Differential diagnosis

    It is important to realize that there is a significant overlap between many neurodegenerative diseases, and that a clear-cut distinction between entities is not always possible. In the case of dementia with Lewy bodies, this is particularly the case, with a strong overlap between:

    • Alzheimer disease
      • clinical: may occasionally have a similar clinical presentation with a frontal type dementia or posterior cortical atrophy
      • imaging: prominent involvement of hippocampi on imaging
    • Parkinson disease
      • clinical: dementia is only a late feature, with parkinsonian symptoms having been present for many years
    • frontotemporal lobar degeneration
      • clinical: usually younger onset, absent parkinsonian features, absent visual hallucinations
      • imaging: more pronounced frontal/temporal atrophy; left-to-right asymmetry 
    Siehe auch:
    und weiter: